Group 1 - FIL Limited increased its stake in Medical Information Technology (医脉通, 02192) by acquiring 2.7155 million shares at a price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million [1] - After the acquisition, FIL Limited's total shareholding in Medical Information Technology reached approximately 37.1726 million shares, representing a stake of 5.04% [1] - The transaction involves related parties: Pandanus Associates Inc. and Pandanus Partners L.P. [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 10 ...

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of 200,000 ordinary shares to a director exercising stock options under the pre-IPO share option plan adopted on March 29, 2021, with the issuance date set for February 27, 2026 [1] Group 1 - The company will issue 200,000 ordinary shares [1] - The issuance is part of the pre-IPO share option plan adopted on March 29, 2021 [1] - The shares will be issued to a director exercising stock options [1]

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of 200,000 ordinary shares to a director exercising stock options under the pre-IPO stock option plan adopted on March 29, 2021 [1] Group 1 - The issuance date for the shares is set for February 27, 2026 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫脈通科技有限公司 呈交日期： 2026年2月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | | ...

Core Viewpoint - Dahua Jixian has initiated coverage on Yimaitong (02192) with a "Buy" rating and a target price of HKD 13.5, corresponding to a projected P/E ratio of approximately 24.1 times for 2026 [1] Company Overview - Yimaitong is recognized as a leading physician platform in China, covering 88% of practicing physicians nationwide [1] - The company operates in a B2B niche market centered around physicians, which complements consumer-focused peers in the industry [1] Financial Projections - The company is expected to maintain a light asset and high-profit margin model, supporting an average annual compound growth rate of 17% in revenue and 15% in adjusted net profit from 2025 to 2027 [1] - Yimaitong's net cash position and high-profit margin outlook are viewed positively, with a potential dividend payout ratio estimated between 50% to 60% [1]

Core Viewpoint - Dahua Jixian has initiated coverage on Yimaitong (02192) with a "Buy" rating and a target price of HKD 13.5, corresponding to a projected P/E ratio of approximately 24.1 times for 2026 [1] Group 1: Company Overview - Yimaitong is recognized as a leading physician platform in China, covering 88% of practicing physicians nationwide [1] - The company operates in a B2B niche market centered around physicians, which complements consumer-focused peers in the industry [1] Group 2: Financial Projections - The company is expected to achieve a compound annual growth rate (CAGR) of 17% in revenue and 15% in adjusted net profit from 2025 to 2027 [1] - Yimaitong's business model is characterized by light asset utilization and high profit margins, supporting its financial growth outlook [1] Group 3: Cash and Dividend Outlook - The company is anticipated to maintain a strong net cash position and high profit margin prospects [1] - Potential dividend payout ratio is estimated to be between 50% and 60% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 醫脈通科技有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | 本月底法 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2026年1月31日 | | --- | | 狀態: | | 新提交 | 致：香港交易及結算所有限公司 公司名稱: 醫脈通科技有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD ...

Summary of Medical Platform Conference Call Company Overview - **Company**: 医脉通 (Yiliao Tong) - **Industry**: Online medical platform for healthcare professionals in China - **User Base**: Over 7 million registered users, with more than 88% being licensed physicians, indicating a high penetration rate within the Chinese medical community [2][3] Key Insights User Engagement and Growth - Monthly active users reached 2.78 million in the first half of 2025, showcasing strong engagement [2] - The platform has covered 506 products, with an average revenue contribution of approximately 1 million RMB per product, indicating significant growth potential [2][10] AI Integration and Product Development - 医脉通 has integrated AI technology into its products, enhancing user experience and efficiency. Daily usage frequency increased by over 20% due to upgrades in clinical guidelines and disease knowledge databases [7][8] - AI services for pharmaceutical companies, such as content generation and review, have started generating revenue, although customer demand is still maturing [7][8] Market Potential - The online precision marketing market for pharmaceuticals is estimated to have around 3,000 applicable products, with a potential growth space of approximately 30 times compared to current levels [4][10] - The company aims to leverage its understanding of physician needs to optimize marketing strategies and enhance service offerings [4][11] Competitive Landscape - 医脉通 differentiates itself through its comprehensive service offerings, including research, content creation, and strategy planning, which are tailored to meet the specific needs of pharmaceutical companies [11][12] - The company has a unique advantage due to its extensive industry experience and understanding of pharmaceutical client needs, allowing it to capture a larger share of marketing budgets [12] Financial Position and Future Plans - As of mid-2025, the company holds approximately 3.1-3.2 billion RMB in cash and cash equivalents, with total assets around 4.6-4.7 billion RMB (approximately 5 billion HKD) [20] - Funds will be allocated for business development, including acquisitions and R&D investments, particularly in post-approval clinical research [20] Customer Base and Expansion - The typical clients include multinational pharmaceutical companies, biotech firms, and traditional pharmaceutical companies, reflecting a diverse customer structure [16] - The company plans to expand its client base further, especially with the rise of domestic biotech firms [16] Comparison with Competitors - 医脉通's business model is compared to OpenEvidence, which primarily relies on advertising. In contrast, 医脉通 offers a more comprehensive service suite, including academic promotion [13] - The company utilizes a self-developed medical model and has a low advertisement loading rate due to limited pharmaceutical budgets, indicating room for growth as budgets increase [14] Future Outlook - While specific forecasts for 2025 and 2026 are not available, the company remains optimistic about its growth trajectory based on current market dynamics and user engagement [21]